3-Dimensional liver volume assessment in patients with hepatitis B virus-related liver cirrhosis during long-term oral nucleos(t)ide analogues therapy

Table 2 Liver volume change according to the independent nominal variables

Variables	No	Pre-Volume	Post-Volume	Volume change	Volume change (%)	P value
Male	34	1089.6 ± 222.6	1210.9 ± 245.0	121.3 ± 189.5	12.6 ± 19.4	0.695
Female	21	838.8 ± 191.3	941.6 ± 202.6	102.8 ± 128.7	13.4 ± 15.5
Initial NUCs: LAM or LdT	32	1022.2 ± 230.6	1125.1 ± 235.7	102.9 ± 155.2	11.4 ± 14.5	0.559
Initial NUCs: ETV	23	954.4 ± 258.8	1084.5 ± 301.4	130.0 ± 186.4	12.9 ± 17.9
Compensated LC	21	1063.8 ± 238.9	1127.9 ± 250.8	64.1 ± 137.7	6.6 ± 12.5	0.081
Decompensated LC	34	950.6 ± 238.4	1095.9 ± 273.6	145.2 ± 178.9	16.7 ± 19.7
CTP grade improvement	31	944.4 ± 224.4	1113.3 ± 271.6	168.9 ± 164.8	18.9 ± 18.8	0.005
No CTP grade improvement	24	1057.7 ± 255.3	1101.4 ± 257.7	43.7 ± 146.6	5.1 ± 13.2
MELD score decrease > 5	17	1012.9 ± 172.6	1209.9 ± 214.2	197.0 ± 199.2	21.1 ± 22.0	0.013
No MELD score decrease > 5	38	985.3 ± 270.0	1062.6 ± 272.8	77.2 ± 139.3	9.2 ± 14.5
HCC development	6	998.3 ± 202.8	990.0 ± 196.8	-9.2 ± 124.3	-0.5 ± 11.3	0.056
No HCC development	49	993.3 ± 249.1	1122.7 ± 268.2	129.4 ± 167.2	14.5 ± 17.9
Virological response	38	974.1 ± 230.2	1111.1 ± 270.3	137.0 ± 162.8	15.1 ± 18.6	0.134
No virological response	17	1038.1 ± 271.0	1101.5 ± 254.8	63.4 ± 172.7	8.0 ± 15.5
Virological breakthrough	13	1064.6 ± 255.3	1091.5 ± 168.7	26.9 ± 153.3	4.9 ± 14.5	0.030
No virological breakthrough	42	971.9 ± 237.7	1113.2 ± 287.8	141.3 ± 164.5	15.4 ± 18.2
Virological resistance	8	992.0 ± 206.0	1059.3 ± 132.5	67.3 ± 129.7	8.9 ± 14.2	0.134
No virological resistance	41	969.0 ± 236.5	1125.0 ± 286.7	156.0 ± 154.1	16.8 ± 17.3
History of stop medication	2	1369.5 ± 44.5	1257.0 ± 141.4	-112.5 ± 96.9	-8.3 ± 7.3	0.051
Continuation of medication	53	979.7 ± 235.7	1102.5 ± 265.9	122.8 ± 164.4	13.7 ± 17.7

LC: Liver cirrhosis; LAM: Lamivudine, LdT: Telbivudine; NUCs: Nucleos(t)ide analogues; ETV: Entecavir; CTP: Child-Turcotte-Pugh; MELD: Model for end-stage liver disease; HCC: Hepatocellular carcinoma.